Thanks @Quitman for that post.
With Relyvrio out of the way. Basically leaves ourselves v Riluzole and Radicava. Riluzole increases median survival by up to 19 months .
Radicava costs $145 K PY . Short half live. 6 months median survival . Folks, that is our opposition now. PAA are now in a unique situation of saying to BP this is what we want in $. That's my read.
Kpax
Amylyx class action Relyvrio
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
17.0¢ |
Change
-0.010(5.56%) |
Mkt cap ! $67.30M | |||
| Open | High | Low | Value | Volume |
| 17.5¢ | 18.0¢ | 16.3¢ | $581.7K | 3.408M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 502428 | 17.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 17.5¢ | 40529 | 1 |
View Market Depth
| Last trade - 16.10pm 10/05/2024 (20 minute delay) ? |
|
|||||
|
Last
17.5¢ |
Change
-0.010 ( 3.15 %) |
||||
| Open | High | Low | Volume | ||
| 17.5¢ | 18.0¢ | 16.0¢ | 3492891 | ||
| Last updated 15.59pm 10/05/2024 ? | |||||
| PAA (ASX) Chart |